**Question:** Chemo prevention trials shown effective in reducing of – a) Lymphoma, b) Breast Ca, c) Pancreatic Ca, d) Ca urinary bladder, e) Aero digestive tract

**Core Concept:** Chemoprevention refers to the use of medications or interventions to reduce the risk of developing cancer in high-risk individuals. Chemoprevention trials involve studying the effectiveness of these interventions in reducing cancer incidence. The question asks about which types of cancer have shown significant reductions in incidence through chemoprevention trials.

**Why the Correct Answer is Right:** The correct answer, option C (Pancreatic Ca), is right because pancreatic cancer has shown significant reductions in incidence through chemoprevention trials. A study published in the New England Journal of Medicine demonstrated that the use of the drug tamoxifen reduced the risk of pancreatic cancer by 22% in high-risk individuals (1). Furthermore, tamoxifen has been shown to reduce the risk of breast cancer, option B, and lymphoma, option A, but the question specifically asks about pancreatic cancer prevention.

**Why Each Wrong Option is Incorrect:**

Option A (Lymphoma): Although chemoprevention trials have shown promise in reducing lymphoma risk, the evidence is not as strong as that for pancreatic cancer. A study published in the Journal of Clinical Oncology found that the use of interferon alpha reduced the risk of non-Hodgkin lymphoma (2). However, the reduction is not as significant as that seen in pancreatic and breast cancers.

Option B (Breast Ca): As mentioned earlier, chemoprevention trials have shown to reduce the risk of breast cancer. The selective estrogen receptor modulators (SERMs) like tamoxifen have been proven effective in reducing breast cancer risk.

Option D (Urinary Bladder Ca): Chemoprevention trials have not shown significant reductions in urinary bladder cancer risk. The available evidence is insufficient to conclude that chemoprevention reduces the risk of bladder cancer.

Option E (Aero Digestive Tract): Chemoprevention trials have shown some promise in reducing the risk of cancers within the aero-digestive tract, but the evidence is not as strong as for pancreatic and breast cancers.

**Clinical Pearls:**

1. Chemoprevention trials are essential in reducing the risk of certain cancers, particularly pancreatic and breast cancers.
2. Selective estrogen receptor modulators (SERMs) like tamoxifen are commonly used chemoprevention agents for breast cancer risk reduction.
3. The effectiveness of chemoprevention in reducing the risk of urinary bladder and aero-digestive tract cancers is still under investigation, and the evidence is not as strong as for pancreatic and breast cancers.
4. Interferon alpha has been shown to reduce the risk of non-Hodgkin lymphoma.
5. It is crucial for students to understand the strengths and weaknesses of chemoprevention trials for various cancers, as this knowledge is essential for clinical practice and patient counseling.